Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties.

By Travis T Wager, Xinjun Hou, P. Verhoest, A. Villalobos. ACS Chemical Neuroscience, 2010

926 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Quantifying the chemical beauty of drugs. (2012, background): “, prioritization of molecular targets, penetration of the central nervous syste”
Current Challenges and Opportunities in Treating Glioblastoma (2018, methodology): “An analysis of FDA-approved CNS drugs demonstrated 74% have a CNS MPO desirability score $4 (Wager et al., 2010).”
The influence of lipophilicity in drug discovery and design (2012, methodology): “Thus if a log P of > 3 were used as a strict cutoff, drug design of appropriate CNS drugs may be significantly restricted [88].”